Paul Choi
Stock Analyst at Goldman Sachs
(3.52)
# 860
Out of 5,126 analysts
109
Total ratings
52.17%
Success rate
5.53%
Average return
Main Sectors:
Stocks Rated by Paul Choi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VERA Vera Therapeutics | Maintains: Buy | $55 → $95 | $43.50 | +118.39% | 1 | Dec 19, 2025 | |
| CYTK Cytokinetics | Upgrades: Buy | $55 → $95 | $62.34 | +52.39% | 3 | Dec 19, 2025 | |
| PTCT PTC Therapeutics | Maintains: Sell | $44 → $50 | $74.68 | -33.05% | 8 | Nov 5, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $55 → $100 | $68.05 | +46.95% | 7 | Oct 31, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Buy | $45 → $55 | $43.09 | +27.64% | 2 | Oct 29, 2025 | |
| ARVN Arvinas | Downgrades: Sell | $8 → $6 | $13.48 | -55.49% | 4 | Oct 15, 2025 | |
| LNTH Lantheus Holdings | Downgrades: Neutral | $110 → $77 | $64.89 | +18.66% | 2 | Oct 8, 2025 | |
| EWTX Edgewise Therapeutics | Initiates: Neutral | $20 | $29.10 | -31.27% | 1 | Sep 25, 2025 | |
| EXEL Exelixis | Initiates: Buy | $47 | $43.90 | +7.06% | 1 | Sep 17, 2025 | |
| AMRN Amarin Corporation | Maintains: Sell | $7 → $12 | $14.75 | -18.64% | 9 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $16 → $3 | $21.35 | -85.95% | 4 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $8 | $2.26 | +253.98% | 6 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $5 | $12.58 | -60.25% | 10 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $52 | $41.42 | +25.54% | 2 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $7.19 | +192.07% | 8 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $12 | $10.33 | +16.17% | 3 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $3 | $3.40 | -11.76% | 9 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $12 → $10 | $15.50 | -35.48% | 4 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $225 | $222.15 | +1.28% | 4 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $19 | $15.18 | +25.16% | 6 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $19 | $5.68 | +234.51% | 3 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $1.04 | +2,303.85% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $151 → $170 | $11.60 | +1,365.52% | 2 | Oct 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $9 → $8 | $6.94 | +15.27% | 4 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $135 | $141.20 | -4.39% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $270 → $300 | $36.81 | +715.00% | 2 | Mar 30, 2020 |
Vera Therapeutics
Dec 19, 2025
Maintains: Buy
Price Target: $55 → $95
Current: $43.50
Upside: +118.39%
Cytokinetics
Dec 19, 2025
Upgrades: Buy
Price Target: $55 → $95
Current: $62.34
Upside: +52.39%
PTC Therapeutics
Nov 5, 2025
Maintains: Sell
Price Target: $44 → $50
Current: $74.68
Upside: -33.05%
BridgeBio Pharma
Oct 31, 2025
Maintains: Buy
Price Target: $55 → $100
Current: $68.05
Upside: +46.95%
Kiniksa Pharmaceuticals International,
Oct 29, 2025
Maintains: Buy
Price Target: $45 → $55
Current: $43.09
Upside: +27.64%
Arvinas
Oct 15, 2025
Downgrades: Sell
Price Target: $8 → $6
Current: $13.48
Upside: -55.49%
Lantheus Holdings
Oct 8, 2025
Downgrades: Neutral
Price Target: $110 → $77
Current: $64.89
Upside: +18.66%
Edgewise Therapeutics
Sep 25, 2025
Initiates: Neutral
Price Target: $20
Current: $29.10
Upside: -31.27%
Exelixis
Sep 17, 2025
Initiates: Buy
Price Target: $47
Current: $43.90
Upside: +7.06%
Amarin Corporation
Jun 25, 2025
Maintains: Sell
Price Target: $7 → $12
Current: $14.75
Upside: -18.64%
May 22, 2025
Maintains: Neutral
Price Target: $16 → $3
Current: $21.35
Upside: -85.95%
May 16, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $2.26
Upside: +253.98%
May 2, 2025
Maintains: Neutral
Price Target: $10 → $5
Current: $12.58
Upside: -60.25%
Apr 17, 2025
Maintains: Buy
Price Target: $60 → $52
Current: $41.42
Upside: +25.54%
Apr 17, 2025
Maintains: Buy
Price Target: $28 → $21
Current: $7.19
Upside: +192.07%
Apr 17, 2025
Maintains: Neutral
Price Target: $14 → $12
Current: $10.33
Upside: +16.17%
Apr 17, 2025
Maintains: Neutral
Price Target: $4 → $3
Current: $3.40
Upside: -11.76%
Apr 17, 2025
Maintains: Sell
Price Target: $12 → $10
Current: $15.50
Upside: -35.48%
Feb 13, 2025
Maintains: Buy
Price Target: $200 → $225
Current: $222.15
Upside: +1.28%
Aug 1, 2024
Maintains: Neutral
Price Target: $17 → $19
Current: $15.18
Upside: +25.16%
Jun 29, 2023
Maintains: Buy
Price Target: $21 → $19
Current: $5.68
Upside: +234.51%
May 24, 2022
Maintains: Buy
Price Target: $43 → $25
Current: $1.04
Upside: +2,303.85%
Oct 6, 2021
Maintains: Buy
Price Target: $151 → $170
Current: $11.60
Upside: +1,365.52%
Aug 6, 2021
Maintains: Sell
Price Target: $9 → $8
Current: $6.94
Upside: +15.27%
Jun 29, 2020
Downgrades: Neutral
Price Target: $135
Current: $141.20
Upside: -4.39%
Mar 30, 2020
Upgrades: Neutral
Price Target: $270 → $300
Current: $36.81
Upside: +715.00%